LAWRENCEVILLE, N.J.,
July 31, 2014 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN) announced today that the
Company will host a conference call to discuss its second quarter
2014 financial results at 11:00 a.m.
EDT on Thursday, August 7,
2014. To participate in the call, interested parties may
dial 1-800-533-7954 (Toll-Free/North
America) or 1-785-830-1924 (International/Toll) and ask for
the Celsion Corporation Second Quarter 2014 Conference Call
(Conference Code: 8283269) to register ten minutes before the call
is scheduled to begin. The call will also be broadcast live on the
internet at http://www.celsion.com.
The call will be archived for replay on Thursday, August 7, 2014 and will remain
available until Thursday, August 21,
2014. The replay can be accessed at 1-888-203-1112
(Toll-Free/North America) or
1-719-457-0820 (International/Toll) using Conference Code: 8283269.
An audio replay of the call will also be available on the Company's
website, http://www.celsion.com, for 30 days after 2:00 p.m. EDT on Thursday,
August 7, 2014.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer. The pipeline also includes EGEN-001, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has three platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies, including TheraPlas™ and
TheraSilence™. For more information on Celsion, visit our
website: http://www.celsion.com.
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
SOURCE Celsion Corporation